Lung cancer trials in France

In France 316 Also abroad 2746

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Bordeaux, Brest, Grenoble Cedex 9, Lille, Marseille, Nantes Cedex 1, Paris, Paris Cedex 20, Rennes, Rouen, Toulouse, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Bordeaux, Dijon, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Paris, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Lille, Lyon, Marseille, Saint-Herblain, Villejuif
Age
18 years and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
Phase 1Taking people
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Where
Toulouse, Villejuif
Age
18 years and over
People
250 worldwide
Run by
Pfizer
See details and how to joinNCT07519655
Phase 1/2Taking people
A 2-part Phase 1/2 Open-label Trial on ODM-212
Where
Bordeaux, Marseille, Poitiers, Villejuif
Age
18 years and over
People
229 worldwide
Run by
Orion Corporation, Orion Pharma
See details and how to joinNCT07563738
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Avignon Cedex 9, Bron, Lille, Lyon, Nancy, Nice Cedex 2, Paris, Pessac, Poitiers, Reims, Rennes Cedex 9, Saint-Herblain Cedex, Strasbourg Cedex, Suresnes, Toulon, Toulouse, Vantoux, Villejuif
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Lyon, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 3Active, not recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Créteil, La Tronche, Lille, Limoges, Montpellier Cedex 5, Mulhouse, Nantes, Nice Cedex 2, Paris, Pierre-Bénite, Saint-Herblain Cedex, Suresnes, Villejuif
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1Suspended
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bobigny, Bron, La Tronche, Lyon Cedex08, Marseille, Nice, Paris, Pessac, Poitiers, Reims, Rennes, Toulouse, Vantoux, Villejuif
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Dijon, Paris, Pierre-Bénite, Villejuif
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 3Not yet taking people in France
Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial
Where
Angers, Aurillac, Bayeux, Bayonne, Bobigny, Bron, Caen Cedex 5, Créteil, Le Chesnay Rocquencourt, Lille, Marseille, Montfermeil, Paris, Rennes, Suresnes, Toulon, Villejuif
Age
18 years and over
People
254
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07915037 · EU 2025-521891-78-00
Phase 3Active, not recruiting
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Angers Cedex 9, Bron, Créteil, Dijon, Grenoble Cedex 9, Lille, Marseille, Montpellier, Paris, Paris Cedex 18, Poitiers, Saint-Herblain, Saint-Mande, Suresnes
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00
Phase 1Taking people
Phase I clinical trial evaluating TG4070 in patients with non-small cell lung cancer
Where
Marseille, Paris, Rennes Cedex 9, Strasbourg Cedex, Toulouse Cedex 9
Age
18 years and over
People
40
Run by
Transgene
See details and how to join2025-520946-31-00
Phase 2Taking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Caen Cedex 5, Nimes Cedex 9, Paris, St Herblain, Villejuif
Age
18 years and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Amiens, Bayonne, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Nancy, Poitiers, Villefranche Sur Saone Cedex
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Brest Cedex 2, Grenoble Cedex 9, Marseille, Saint-Herblain Cedex
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
Phase 2Taking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Brest, Marseille, Paris, Rouen Cedex, Villejuif
Age
18 years and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Bron, Lyon Cedex 04, Marseille, Paris, Pierre-Bénite
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2/3Not yet taking people in France
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Montpellier Cedex 5, Mougins, Paris, Villefranche Sur Saone Cedex, Villejuif
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
No phaseTaking people
ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer
Where
Lyon, Villefranche-sur-Saône
Age
18 years and over
People
40
Run by
Centre Leon Berard
See details and how to joinNCT07786909
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Angers, Bayonne, Bordeaux, Bordeaux Cedex, Bron, Caen, Caen Cedex 5, Clermont-Ferrand, Créteil, Dijon, Grenoble Cedex 9, Limoges Cedex 1, Marseille, Mulhouse, Paris, Rennes Cedex 9, Saint-Herblain, Saint-Herblain Cedex, Strasbourg, Suresnes, Toulon, Toulon Cedex 9, Villejuif
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Not yet taking people in France
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Bordeaux, Bordeaux Cedex, Marseille Cedex 20, Montpellier, Nancy, Nantes Cedex 2, Nice Cedex 2, Paris, Pierre-Bénite, Rennes, Saint-Herblain, Saint-Herblain Cedex, Strasbourg, Villefranche Sur Saone Cedex
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Bron, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Bron, Marseille, Paris, Rennes Cedex 9, Saint-Herblain, Strasbourg, Toulouse, Villejuif
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00